Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac

This study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional non-steroidal anti-inflammatory drug diclofenac in the symptomatic treatment of viral pharyngitis. Adult patients from 27 study centers in Latin America were treated with oral doses...

Descripción completa

Detalles Bibliográficos
Autores Principales: Weckx L.L.M., Ruiz J.E., Duperly J., Martínez Mendizabal G.A., Rausis M.B.G., Piltcher S.L., Saffer M., Matsuyama C., Levy S., Fort J.G.
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: 2002
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/22385
https://doi.org/10.1177/147323000203000212
id ir-10336-22385
recordtype dspace
spelling ir-10336-223852022-05-02T12:37:19Z Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac Weckx L.L.M. Ruiz J.E. Duperly J. Martínez Mendizabal G.A. Rausis M.B.G. Piltcher S.L. Saffer M. Matsuyama C. Levy S. Fort J.G. Celecoxib Cyclooxygenase 2 inhibitor Diclofenac Nonsteroid antiinflammatory agent Celecoxib Diclofenac Nonsteroid antiinflammatory agent Prostaglandin synthase inhibitor Pyrazole derivative Sulfonamide Adult Article Clinical trial Controlled clinical trial Controlled study Double blind procedure Drug efficacy Drug safety Drug withdrawal Dysphonia Female Fever Gastrointestinal disease Headache Human Incidence Major clinical study Male Multicenter study Nose congestion Patient satisfaction Pharyngitis Quality of life Randomized controlled trial Sinusitis Sore throat South and central america Swallowing Symptom Vertigo Visual analog scale Adolescent Aged Cohort analysis Comparative study Middle aged Pain assessment Pathophysiology Treatment outcome Virus infection Adolescent Adult Aged Cohort studies Cyclooxygenase inhibitors Diclofenac Double-blind method Female Humans Male Middle aged Pain measurement Pharyngitis Pyrazoles Quality of life Sulfonamides Treatment outcome Virus diseases Celecoxib Cyclooxygenase (cox)-2 specific inhibitors Symptomatic treatment Throat pain on swallowing Viral pharyngitis non-steroidal Anti-inflammatory agents This study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional non-steroidal anti-inflammatory drug diclofenac in the symptomatic treatment of viral pharyngitis. Adult patients from 27 study centers in Latin America were treated with oral doses of celecoxib 200 mg once daily or 200 mg twice daily, or diclofenac 75 mg twice daily for 5 days in a double-blind, randomized study. The primary efficacy assessment was 'Throat Pain on Swallowing' on day 3. In addition, secondary quality-of-life assessments were performed on days 3 and 5. All adverse events and treatment-emergent signs and symptoms were recorded. Data from 313 patients were evaluable for efficacy (105 celecoxib 200 mg once daily, 107 celecoxib 200 mg twice daily, 101 diclofenac 75 mg twice daily). The upper 95% confidence limits for the visual analog scale of 'Throat Pain on Swallowing' on day 3 for celecoxib 200 mg once daily relative to diclofenac 75 mg twice daily, and celecoxib 200 mg twice daily relative to diclofenac 75 mg twice daily were 9.26 and 7.83, respectively. All secondary efficacy and quality-of-life measures were clinically similar for the three treatment groups, and no statistically significant differences were detected. The incidences of treatment-emergent adverse events and withdrawals due to adverse events were similar for all groups, but numerically higher among patients taking diclofenac than celecoxib. More patients in the diclofenac group reported gastrointestinal complaints (7.3%) compared with those in the celecoxib groups (4.3% in the celecoxib 200 mg once-daily group and 3.4% in the celecoxib 200 mg twice-daily group). In conclusion, 5 days of treatment with celecoxib 200 mg once daily is as effective as diclofenac 75 mg twice daily in the symptomatic treatment of viral pharyngitis. Celecoxib 200 mg once daily is also as effective as celecoxib 200 mg twice daily in this condition. 2002 2020-05-25T23:56:17Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 3000605 https://repository.urosario.edu.co/handle/10336/22385 https://doi.org/10.1177/147323000203000212 eng info:eu-repo/semantics/openAccess application/pdf instname:Universidad del Rosario
institution EdocUR - Universidad del Rosario
collection DSpace
language Inglés (English)
topic Celecoxib
Cyclooxygenase 2 inhibitor
Diclofenac
Nonsteroid antiinflammatory agent
Celecoxib
Diclofenac
Nonsteroid antiinflammatory agent
Prostaglandin synthase inhibitor
Pyrazole derivative
Sulfonamide
Adult
Article
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Drug safety
Drug withdrawal
Dysphonia
Female
Fever
Gastrointestinal disease
Headache
Human
Incidence
Major clinical study
Male
Multicenter study
Nose congestion
Patient satisfaction
Pharyngitis
Quality of life
Randomized controlled trial
Sinusitis
Sore throat
South and central america
Swallowing
Symptom
Vertigo
Visual analog scale
Adolescent
Aged
Cohort analysis
Comparative study
Middle aged
Pain assessment
Pathophysiology
Treatment outcome
Virus infection
Adolescent
Adult
Aged
Cohort studies
Cyclooxygenase inhibitors
Diclofenac
Double-blind method
Female
Humans
Male
Middle aged
Pain measurement
Pharyngitis
Pyrazoles
Quality of life
Sulfonamides
Treatment outcome
Virus diseases
Celecoxib
Cyclooxygenase (cox)-2 specific inhibitors
Symptomatic treatment
Throat pain on swallowing
Viral pharyngitis
non-steroidal
Anti-inflammatory agents
spellingShingle Celecoxib
Cyclooxygenase 2 inhibitor
Diclofenac
Nonsteroid antiinflammatory agent
Celecoxib
Diclofenac
Nonsteroid antiinflammatory agent
Prostaglandin synthase inhibitor
Pyrazole derivative
Sulfonamide
Adult
Article
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Drug safety
Drug withdrawal
Dysphonia
Female
Fever
Gastrointestinal disease
Headache
Human
Incidence
Major clinical study
Male
Multicenter study
Nose congestion
Patient satisfaction
Pharyngitis
Quality of life
Randomized controlled trial
Sinusitis
Sore throat
South and central america
Swallowing
Symptom
Vertigo
Visual analog scale
Adolescent
Aged
Cohort analysis
Comparative study
Middle aged
Pain assessment
Pathophysiology
Treatment outcome
Virus infection
Adolescent
Adult
Aged
Cohort studies
Cyclooxygenase inhibitors
Diclofenac
Double-blind method
Female
Humans
Male
Middle aged
Pain measurement
Pharyngitis
Pyrazoles
Quality of life
Sulfonamides
Treatment outcome
Virus diseases
Celecoxib
Cyclooxygenase (cox)-2 specific inhibitors
Symptomatic treatment
Throat pain on swallowing
Viral pharyngitis
non-steroidal
Anti-inflammatory agents
Weckx L.L.M.
Ruiz J.E.
Duperly J.
Martínez Mendizabal G.A.
Rausis M.B.G.
Piltcher S.L.
Saffer M.
Matsuyama C.
Levy S.
Fort J.G.
Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac
description This study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional non-steroidal anti-inflammatory drug diclofenac in the symptomatic treatment of viral pharyngitis. Adult patients from 27 study centers in Latin America were treated with oral doses of celecoxib 200 mg once daily or 200 mg twice daily, or diclofenac 75 mg twice daily for 5 days in a double-blind, randomized study. The primary efficacy assessment was 'Throat Pain on Swallowing' on day 3. In addition, secondary quality-of-life assessments were performed on days 3 and 5. All adverse events and treatment-emergent signs and symptoms were recorded. Data from 313 patients were evaluable for efficacy (105 celecoxib 200 mg once daily, 107 celecoxib 200 mg twice daily, 101 diclofenac 75 mg twice daily). The upper 95% confidence limits for the visual analog scale of 'Throat Pain on Swallowing' on day 3 for celecoxib 200 mg once daily relative to diclofenac 75 mg twice daily, and celecoxib 200 mg twice daily relative to diclofenac 75 mg twice daily were 9.26 and 7.83, respectively. All secondary efficacy and quality-of-life measures were clinically similar for the three treatment groups, and no statistically significant differences were detected. The incidences of treatment-emergent adverse events and withdrawals due to adverse events were similar for all groups, but numerically higher among patients taking diclofenac than celecoxib. More patients in the diclofenac group reported gastrointestinal complaints (7.3%) compared with those in the celecoxib groups (4.3% in the celecoxib 200 mg once-daily group and 3.4% in the celecoxib 200 mg twice-daily group). In conclusion, 5 days of treatment with celecoxib 200 mg once daily is as effective as diclofenac 75 mg twice daily in the symptomatic treatment of viral pharyngitis. Celecoxib 200 mg once daily is also as effective as celecoxib 200 mg twice daily in this condition.
format Artículo (Article)
author Weckx L.L.M.
Ruiz J.E.
Duperly J.
Martínez Mendizabal G.A.
Rausis M.B.G.
Piltcher S.L.
Saffer M.
Matsuyama C.
Levy S.
Fort J.G.
author_facet Weckx L.L.M.
Ruiz J.E.
Duperly J.
Martínez Mendizabal G.A.
Rausis M.B.G.
Piltcher S.L.
Saffer M.
Matsuyama C.
Levy S.
Fort J.G.
author_sort Weckx L.L.M.
title Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac
title_short Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac
title_full Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac
title_fullStr Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac
title_full_unstemmed Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac
title_sort efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac
publishDate 2002
url https://repository.urosario.edu.co/handle/10336/22385
https://doi.org/10.1177/147323000203000212
_version_ 1740172039027687424
score 12,131701